Global Antiparasitic Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Antiparasitic Drugs Market is presumed to reach the market size of nearly USD 31.29 Billion by 2032 from USD 18.3 Billion in 2023 with a CAGR of 6.14% under the study period 2024 - 2032.

Antiparasitic drugs are medications designed to treat infections caused by parasites, including protozoa, helminths, and arthropods. These drugs work by either killing or inhibiting the growth of parasites within the host organism. Common examples include antimalarials, anthelmintics, and antiprotozoals. These drugs are essential in combating parasitic diseases, contributing to public health efforts, and improving the well-being of affected individuals.

MARKET DYNAMICS

The Antiparasitic drugs market is propelled by factors such as the prevalence of parasitic infections, increasing awareness of neglected tropical diseases, and advancements in drug development. The global burden of parasitic diseases, including malaria, leishmaniasis, and helminth infections, drives the demand for effective antiparasitic medications. Government initiatives and international collaborations focusing on eliminating parasitic diseases further contribute to market growth. Research and development efforts to discover novel antiparasitic drugs and the introduction of combination therapies enhance treatment options. The market is also influenced by socioeconomic factors, as parasitic infections disproportionately affect populations in low-income regions. The increasing emphasis on One Health strategies, which acknowledge the interconnectedness of human, animal, and environmental health, highlights the crucial role of antiparasitic drugs in global health initiatives. These medications play a pivotal role in addressing and managing health challenges that transcend species boundaries, contributing to comprehensive efforts aimed at improving overall public health on a global scale.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of antiparasitic drugs. The growth and trends of antiparasitic drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the antiparasitic drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

HIV
Hepatitis
By Influenza
TB
Malaria
HPV

By End Use

Hospitals
Clinics
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antiparasitic Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antiparasitic Drugs market include Novartis AG., Gilead, GlaxoSmithKline plc., Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals, Inc., Merck & Co., Inc., Boehringer Ingelheim GmbH. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112113746

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ANTIPARASITIC DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Disease Type
- 3.7.2 Market Attractiveness Analysis By End Use
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTIPARASITIC DRUGS MARKET ANALYSIS BY DISEASE TYPE

5.1 Overview by Disease Type
5.2 Historical and Forecast Data
5.3 Analysis by Disease Type
5.4 HIV Historic and Forecast Sales by Regions
5.5 Hepatitis Historic and Forecast Sales by Regions
5.6 Influenza Historic and Forecast Sales by Regions
5.7 TB Historic and Forecast Sales by Regions
5.8 Malaria Historic and Forecast Sales by Regions
5.9 HPV Historic and Forecast Sales by Regions

6 . GLOBAL ANTIPARASITIC DRUGS MARKET ANALYSIS BY END USE

6.1 Overview by End Use
6.2 Historical and Forecast Data
6.3 Analysis by End Use
6.4 Hospitals Historic and Forecast Sales by Regions
6.5 Clinics Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL ANTIPARASITIC DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ANTIPARASITIC DRUGS COMPANIES

8.1. Antiparasitic Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF ANTIPARASITIC DRUGS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Novartis AG.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Gilead
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. GlaxoSmithKline plc.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Janssen Pharmaceutical Inc.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. F. Hoffmann-La Roche Ltd.
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. BioCryst Pharmaceuticals Inc.
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Merck & Co. Inc.
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Boehringer Ingelheim GmbH.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies